A framework for the quantitative weight-of-evidence (QWoE) analysis of 'omics data for regulatory purposes is presented. The QWoE framework encompasses seven steps to evaluate 'omics data (also together with non-'omics data): (1) Hypothesis formulation, identification and weighting of lines of evidence (LoEs). LoEs conjoin different (types of) studies that are used to critically test the hypothesis. As an essential component of the QWoE framework, step 1 includes the development of templates for scoring sheets that predefine scoring criteria with scores of 0e4 to enable a quantitative determination of study quality and data relevance; (2) literature searches and categorisation of studies into the predefined LoEs; (3) and (4) quantitative assessment of study quality and data relevance using the respective pre-defined scoring sheets for each study; (5) evaluation of LoE-specific strength of evidence based upon the study quality and study relevance scores of the studies conjoined in the respective LoE; (6) integration of the strength of evidence from the individual LoEs to determine the overall strength of evidence; (7) characterisation of uncertainties and conclusion on the QWoE. To put the QWoE framework in practice, case studies are recommended to confirm the relevance of its different steps, or to adapt them as necessary.
1. Introduction
'Omics methodologies and weight-of-evidence approaches
'Omics technologies are not only relevant tools for research, but also for regulatory toxicity testing. Nevertheless, to date, 'omicsbased studies are generally not used to fulfil standard information requirements implemented in substance-specific legislation, such as Regulation (EC) No 1907/2006 on the Registration, Evaluation, Authorisation, and Restriction of Chemicals (REACH; EP and Council of the EU, 2006) . The regulatory applicability of any new technology or test method implies standardisation and validation efforts that 'omics technologies have not yet been submitted to (cf. Sauer et al. (2017) in this journal Supplement). Further, new test methods (or updates of existing test methods to include, e.g., 'omics technologies) may only be used to meet legal standard information requirements if they have been formally accepted for regulatory use. To date, there are no test methods using 'omics technologies that have been adopted, e.g., as Organisation for Economic Cooperation and Development (OECD) Test Guidelines (TGs). Similarly, as regards applicability under REACH, hitherto, no test methods using 'omics technologies have been taken up into Regulation (EC) No 440/2008 laying down test methods pursuant to REACH (Test Methods Regulation; Council of the EU, 2008) .
Test methods that have not yet been adopted as OECD TGs or taken up into the Test Methods Regulation may nevertheless be used under REACH, if they form part of weight-of-evidence (WoE) approaches. In WoE approaches, an overall appraisal of all data that are available at a given point in time is used to come to a conclusion that a specific substance may or may not have a hazardous property. Further, WoE approaches can also be used to improve the understanding of the specific modes-of-action (MoAs; cf. Section 4 for definition) by which a substance elicits toxicity.
However, WoE evaluations do not have the same standing under REACH as data that were collected using test methods listed in the Test Methods Regulation. Generally, regulators are required to assess the sufficiency of WoE approaches in the course of compliance checks of registrations with respect to adaptations to the standard testing regimen, and they may request further testing, if considered necessary (Sauer et al., 2016 .
To date, there are no formal procedures on how to conduct WoE evaluations or on how to assess the sufficiency of evidence. Risk assessors and regulatory authorities may use the term WoE to describe assessments for which very divergent levels of scope and detail are evident, leading to a lack of clarity in the process and conclusions (Agerstrand and Beronius, 2016) . Similarly, the term strength of evidence may be used differently in different documents, and it is sometimes even used interchangeably with WoE (Willhite, 2001; Weed, 2005; Goodman and Lynch, 2017) . For such reasons, there has been a growing interest in the formal application of WoE for regulatory hazard assessment since a formal framework would serve to ensure consistency and transparency on the conclusions derived from the WoE evaluations (Weed, 2005; Linkov et al., 2009; SCENIHR, 2012; Money et al., 2013; Cogliano, 2014) . Considering that 'omics technologies have not yet been adopted to fulfil legally implemented standard information requirements, a formal framework that specifically describes how WoE approaches that include 'omics data should be conducted, appears as an effective means to facilitate their regulatory applicability.
The fields of medicine and engineering have led the way in developing objective frameworks that utilise a formalised WoE approach to perform a 'systematic review' of data on best practice (Bradford Hill, 1965; Higgins and Green, 2011; IOM, 2011; Nichols et al., 2013; NTP, 2013 NTP, , 2015 Prueitt et al., 2014; Rooney et al., 2014; UCSF, 2014) . For chemical substances, the considerations by Bradford Hill (1965) have been tailored for use in the World Health Organisation (WHO)/International Programme on Chemical Safety (IPCS) framework on MoA/species concordance analysis (SonichMullin et al., 2001; Boobis et al., 2009; Meek et al., 2014a, b; Becker et al., 2017) . The modified Bradford Hill considerations describe the following criteria to determine the sufficiency of the evidence for a specific MoA (Meek et al., 2014b) :
Consistency: Is the pattern of effects across species/strains/organs/test systems what would be expected? Essentiality of key events: Is the sequence of events reversible if dosing is stopped or a key event prevented? Temporal concordance: Are the key events observed in hypothesised order? Doseeresponse concordance: Are the key events observed at doses below or similar to those associated with the end (adverse) effect? Biological concordance: Does the hypothesised MoA conflict with broader biological knowledge? How well established is the MoA in the wider biological context? Analogy: Would the MoA be anticipated based on broader chemical specific knowledge? Incidence concordance: Is the occurrence of the end (adverse) effect less than that for preceding key events?
The WHO/IPCS framework, that includes the modified Bradford Hill considerations, has been developed to increase transparency in systematically considering data on MoA for substance-induced adverse effects and their relevance to humans within WoE evaluations (Meek et al., 2014b) . While the WHO/IPCS framework has proven valuable in fostering systematic WoE evaluations, it does not provide a formal structure by which the WoE can be quantitatively determined.
A formal framework enabling quantitative, and not only qualitative, WoE evaluations appears especially important when a broad variety of different types of studies, or studies using nonstandardised test methods and non-standardised technologies, such as 'omics technologies, are used. To account for the diversity of test systems and test methods, transparency is required on the relative weighting that is given to specific types of studies and the respective data they yield. Whenever WoE evaluations are to be applied in a regulatory context, it must be ensured that their outcomes are consistent and reproducible irrespective of the scientist or regulator undertaking the assessment. However, to date, such a formal, quantitative WoE (QWoE) framework is unavailable.
Against this background, the establishment of a generic framework for a QWoE analysis of 'omics data during regulatory hazard assessment was one of the key objectives of the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) workshop Applying 'omics technologies in chemical risk assessment, that took place on 10e12 October 2016 in Madrid, Spain (Fig. 1) . The report of this workshop is provided in Buesen et al. (2017) in this journal Supplement. Ahead of the ECETOC workshop, a first draft of a QWoE framework was developed that was presented and further discussed during the workshop. This draft was founded on a QWoE framework developed for hazard assessment in general, without specific consideration of 'omics-based studies. This general QWoE framework has been trialled successfully for human hazard assessment using animal reproductive toxicity studies (Dekant and Bridges, 2016a, b) and the environmental hazard assessment of persistent, bioaccumulative, toxic substances (Bridges and Solomon, 2016) . At the ECETOC workshop, participants provided recommendations on how to advance the draft framework for a QWoE analysis of 'omics data. These recommendations were addressed in updating the first draft, yielding the present article.
The framework for a QWoE analysis of 'omics data aims at objectifying estimations of the 'sufficiency' of WoE approaches to derive a specific conclusion. Depending on the hypothesis under investigation, the conclusion from the QWoE evaluation can either be related to the presence or absence of a given hazardous property (at a given dose or concentration) or the determination of specific MoAs. The quantitative methodology applied in the QWoE framework serves to increase transparency on the data that are being used for hazard assessment, and it is suitable for utilising 'omics data (alone or combined with non-'omics data) from a variety of different sources and different test systems. All the available data are included in the QWoE evaluation, both from peer-reviewed publications and company reports and both using standardised and non-standardised test methods (Borenius et al., 2014) . By using pre-defined scoring systems, the QWoE framework provides a standardised approach to assess the quality (reliability) of studies, the relevance of findings, and the sufficiency of the evidence to derive a given conclusion.
Importantly, the QWoE framework is not intended to be prescriptive, but instead to provide a baseline level on how to perform a WoE evaluation that includes 'omics-based studies. Deviations from, e.g., the defined scoring grades are possible with justification. In such justifications, reference to the scoring grade from which it deviated, will provide transparency on the decisions taken. Further, the QWoE framework must assert itself in practice. As experience in applying the QWoE framework is gained, the grading schemes may be adapted to accommodate new insight, e.g., into the relevance of specific 'omics findings in a given context or into further criteria that should be taken into consideration in assessing data relevance.
The framework for a quantitative weight-of-evidence analysis of 'omics data
The framework for a QWoE analysis of 'omics data follows the four phases of WoE analyses defined by Rhomberg et al. (2013) , i.e. (i) define causal question and develop criteria for study selection; (ii) develop and apply criteria for review of individual studies; (i) integrate and evaluate evidence; (iv) draw conclusions based on inferences. Specifically, the QWoE framework encompasses the following steps that are presented in further detail in the following sub-sections ( Fig. 2 
):
Step 1: Hypothesis formulation, identification and weighting of lines of evidence (LoEs), and development of templates for scoring sheets;
Step 2: Literature searches and categorisation of studies into LoEs;
Step 3: Assessment of study quality;
Step 4: Assessment of data relevance;
Step 5: Evaluation of the strength of evidence; individual LoEs;
Step 6: Evaluation of the overall strength of evidence; integration of LoEs;
Step 7: Characterisation of uncertainties; conclusion on the QWoE.
The following discussion on how to conduct the seven steps of the QWoE framework assumes that a data-rich substance is submitted for the evaluation. Generally, the QWoE framework has been developed with a focus on human toxicology. Nevertheless, the QWoE framework is equally applicable for ecotoxicological assessments. WoE evaluations of data-poor substances, that include, e.g., the application of read-across techniques (ECHA, 2015) to fill data gaps by comparisons with well-studied reference substances (benchmark materials) are neither covered by the scope of this article, nor by that of the ECETOC workshop. Similarly, risk assessment is also not covered by the scope of this article, or by that of the ECETOC workshop.
2.1.
Step 1: hypothesis formulation; identification and weighting of lines of evidence; development of templates for scoring sheets 2.1.1. Hypothesis formulation Any hazard assessment needs to address a specific hypothesis or problem (Rhomberg et al., 2010 (Rhomberg et al., , 2013 Borgert et al., 2011; Rhomberg, 2015) . The hypothesis may be formulated as a scientific proposition or causal question, or it may simply describe a regulatory requirement (and the corresponding regulatory task to be undertaken). It is vital that the hypothesis is formulated as positive statement (e.g. substance A causes effect B) and that it is defined precisely. If 'omics data are included in the overall assessment, or even form an essential part of it, the hypothesis should provide the rationale for this. In such cases, the causal question may be formulated with respect to the 'omics-based characterisation of transcriptional (transcriptomics), translational (proteomics), or functional (metabolomics) alterations.
The formulation of the hypothesis should take into account the identity and the physico-chemical characteristics of the substance under investigation (assuming that the test substance has been fully characterised prior to the application of the QWoE). Fig. 1 . Overview of the work streams considered at the ECETOC workshop Applying 'omics technologies in chemical risk assessment (Buesen et al., 2017) . The present article Framework for a quantitative weight-of-evidence analysis of 'omics data during regulatory hazard assessment specifically considers discussions from the ECETOC workshop work stream 4 (highlighted in grey).
Finally, the hypothesis should be formulated in a way that it can be tested by experimental studies (in vivo and/or in vitro) and/or in silico modelling.
Identification of lines of evidence
Using the formulated hypothesis, the first issue is to identify the LoEs (cf. Section 4 for definition) that are essential or supportive to critically test the hypothesis. Individual LoEs may conjoin (experimental or epidemiological) human data, animal test data, or in vitro data that may each be related to a toxicological endpoint and/or a specific adverse effect (Fig. 3) . Alternatively, individual LoEs may conjoin specific mechanistic data that provide information on a specific MoA. Similarly, LoEs may conjoin toxicokinetic data on the absorption, distribution, metabolism and elimination (ADME) of the substance. If available, a further LoE should conjoin data on suitable reference substances. The number and types of LoEs that need to be considered varies according to the hypothesis (e.g., whether it serves hazard identification for classification and labelling, for the determination of a point-of-departure for derivedno-effect-levels or the identification of MoA; cf. Sauer et al. (2017) in this journal Supplement). Further, in a QWoE analysis using 'omics data, for each LoE, it should be indicated which types of 'omics data are relevant to critically test the hypothesis, and if 'omics data are the sole data likely to be available or whether they are one among several types of measurements.
Weighting of lines of evidence
For each pre-determined LoE, it should be indicated whether it is (i) essential or (ii) supportive to critically test the hypothesis. Further, the LoEs should be weighted to establish a rank order of their expected importance to critically test the hypothesis. In all cases, the hierarchy assigned to the LoEs should be clearly identified and justified. This weighting should reflect the state of scientific knowledge and the acceptability of the individual LoE for a given purpose.
If the hypothesis relates to human hazard assessment, it may be appropriate to assign LoEs that conjoin high quality human volunteer studies or epidemiological studies the highest weighting. Animal toxicity studies are generally ranked lower than human volunteer studies or epidemiological studies, but are still generally weighted higher than, e.g., in vitro cell culture studies because they include the assessment of various tissues, organ systems and their interactions with each other (Fig. 3) . Importantly, the ranking of LoEs should always take into account the quality of the studies. In particular, low quality, observational human epidemiological studies should not be given higher ranking than well-designed and conducted animal toxicity studies.
Accordingly, the weighting of the LoEs used in a given QWoE evaluation to critically test a hypothesis that is related to human hazard assessment can be conducted taking into account the following weighting criteria:
Essential LoEs are assigned greater weight (higher ranking) than supportive LoEs. LoEs encompassing test methods/test systems that more closely resemble the situation in humans (or are of higher environmental relevance) are given higher ranking than test methods/ test systems that do not resemble the situation in humans. In case different LoEs encompass similar test methods/test systems, those LoEs that include Good Laboratory Practicecompliant, TG-conform test methods (thereby yielding high average study quality scores; calculated in Step 5; Section 2.5) are given higher ranking than those LoEs that include nonstandardised test methods (thereby presumably yielding lower average study quality scores).
If the focus of the QWoE assessment is to critically test a hypothesis that focuses on the elucidation of MoAs, the LoEs may be ranked by their likely importance to identify, e.g., key events of the MoA and to anchor early key events of the MoA to adverse effects (Becker et al., 2017) .
If the hypothesis doesn't enable a ranking order for the weighting of LoEs, the default position is to dispense with weighting. On a case-by-case basis, a weighting may be based on the average study relevance scores for each LoE (Step 5; Section 2.5). Because the weighting of LoEs is liable to bias, the scientific rationale for any weighting must be spelt out.
Development of templates for scoring sheets
For each LoE, templates for distinct scoring sheets to assess (i) the quality of studies and (ii) the relevance of (non-'omics or 'omics) data need to be available prior to the application of the QWoE framework (cf. Section 4 for definitions of the terms quality and relevance). The templates for the scoring sheets are designed to include a pre-defined set of scoring criteria and to specify the prerequisites for assigning scoring grades of 0e4 to each of the scoring criteria. This formal system serves to ensure a high level of transparency, objectivity and consistency of the evaluations (cf. Sections 2.3 and 2.4 for further details on the design and use of the formal scoring systems).
Generally, the templates for the scoring sheets should be This Figure exemplarily represents different LoEs; each oval corresponds to a specific LoE. On a case-by-case basis, it has to be decided which types of 'omics data are relevant to critically test the given hypothesis. Specific LoEs are ranked for their importance to critically test the hypothesis. In this image, LoEs (ovals) that are placed in higher rows generally have higher ranks. Further, LoEs are ranked by whether they are essential or supportive. In this Figure, the left-hand column reflects essential LoEs, whereas the three columns to the right reflect supportive LoEs; Abbreviations: ADME: Absorption, distribution, metabolism, elimination; LoE: Line of evidence.
developed by subject matter experts that are familiar with the methodologies employed and their application to hazard assessment. The templates of the scoring sheets should reflect best practice, and they should adhere to standardised approaches. Accordingly, the templates for the scoring sheets should be founded on an evaluation of reviews and guidance documents relating to those test methods and methodologies that are used to generate the respective data, such as OECD TGs and OECD Guidance Documents. Importantly, the templates for the scoring sheets should not be founded on any study in which the substance of interest was tested to avoid introducing bias by tailoring scoring criteria to a too narrow purpose. Table 1 exemplarily presents a template for a scoring sheet to assess the quality of an animal toxicity study that involves the gathering of 'omics data. Similarly, Table 2 exemplarily presents a template for a scoring sheet to assess the relevance of ('omics and non-'omics) data from an animal toxicity study. These scoring sheets were developed and used in the context of the in vivo reproductive toxicity studies published by Dekant and Bridges (2016a, b) , and they have been adapted to include consideration of 'omics data. Importantly, the scoring sheets reproduced in Tables 1 and 2 are only presented exemplarily. In order to be used in any specific WoE evaluation, they should be modified in accordance with the hypothesis under investigation.
2.2.
Step 2: literature search and categorisation of studies into lines of evidence 2.2.1. Literature search
The identification of essential (and helpful) LoEs allows determining the scope of the literature search. The search should be as comprehensive as is practicable. For each LoE, all potentially relevant studies should be collected and identified. Potentially relevant studies can include 'omics data and/or non-'omics data, and they can be derived from standardised or non-standardised test methods that may be reported in, e.g., unpublished study reports or peer review publications.
Data collection should follow best scientific principles, such as Table 1 Exemplary scoring sheet to assess the quality of an animal study involving the gathering of 'omics data.
Scoring criterion Score to assess study quality with respect to the individual scoring criteria those outlined in the Cochrane systematic review procedure (Higgins and Green, 2011; Lynch et al., 2016 ). An informed choice of search terms for the effects of concern is a prerequisite. Similarly, substance-specific search terms should not only include the substance's chemical names and synonyms, but also its Chemical Abstract Services (CAS) number (and/or Medical Subject Headings (MeSH; https://www.ncbi.nlm.nih.gov/mesh) or PubChem Compound Identifier (CID; https://pubchem.ncbi.nlm.nih.gov/search/ help_search.html), if applicable). If the substance under investigation has not been assigned an unambiguous CAS number, it is essential that the chemical structure is clearly specified in the respective studies.
Categorisation of studies into lines of evidence
Once all potentially relevant studies have been identified, they should be categorised into the pre-defined LoEs. Depending on the available database, one or more studies can be assigned into individual LoEs. In applying the QWoE framework to evaluate 'omics data, the first issue to address is whether only 'omics data are available in a given study, or both 'omics and non-'omics data. 'Omics data may be categorised according to the type of 'omics measurement (e.g., transcriptomics, proteomics, metabolomics).
The following sections are based on the premise that 'omics data form part of an overall assessment that includes non-'omics data. Hence, the QWoE framework is aligned to objectify the relative weighting to be given to 'omics data in a study where non-'omics parameters have also been examined.
2.3.
Step 3: assessment of study quality All published and unpublished studies that were retrieved as an outcome of the comprehensive literature search are categorised according to their quality (reliability). The quality of any given study can both be affected by the way it is designed and by the way it is reported (Klimisch et al., 1997; Kase et al., 2016; Moermond et al., 2016) . Generally, the quality assessment comprises three main aspects, i.e. the level of characterisation of the substance of interest and of substance properties that may compromise the outcome of the study (e.g. volatility, stability, impurities); the appropriateness of the test system for testing the hypothesis; and the reliability of the study results. Using the template for the scoring sheet to assess study quality that was developed for the given QWoE evaluation, the final study quality score is assessed and calculated as is exemplarily described in Box 1. Table 2 Exemplary scoring sheet to assess the relevance of 'omics (or non-'omics) data from an animal toxicity study.
Scoring criterion
Score to assess relevance of findings with respect to the scoring criteria The approach to divide the total score by the number of applicable scoring categories yielding the final study quality score (Box 1), fosters comparability of the quality of different types of studies that are included in different LoEs (Step 6; Section 2.6). Different types of studies are assessed using different scoring sheets that do not necessarily include the same number of scoring categories. If the total score would be used for the overall evaluation, studies encompassing more scoring criteria would be more likely to yield high final quality scores than studies encompassing fewer scoring criteria.
2.4.
Step 4: assessment of data relevance 2.4.1. Determination of potentially relevant findings
The assessment of the relevance of data first involves determining the presence (or absence) of findings that may potentially be relevant to support or decline the hypothesis. This determination involves expert judgement and has to be performed on a case-bycase basis. If the hypothesis is related to hazard identification, the presence (or absence) of adverse effects should be determined as described by ECETOC (2002) that further provide guidance on how to distinguish adverse from adaptive effects (cf. Section 4 for definitions of adverse effects and adaptive effects). However, as also highlighted at the ECETOC workshop Applying 'omics technologies in chemicals risk assessment (Buesen et al., 2017 ; in this journal Supplement), knowledge on how, e.g., gene expression changes can be linked to phenotypic alterations is just beginning to evolve. For the time being, it is likely that 'omics data are predominantly used to critically test hypotheses that are related to potential MoAs of substances.
Assessment of the relevance of 'omics data
Once all potentially relevant findings have been identified, the quantitative relevance of findings to test the hypothesis is assessed using the pre-defined template for the data relevance scoring sheet. The data relevance scoring sheet exemplified in Table 2 covers the following 7 scoring criteria to assess the relevance of 'omics-based findings from an animal toxicity study. These scoring criteria have been adapted from the modified Bradford Hill considerations (Meek et al., 2014a, b ; Section 1) to specifically address the scenario that tissue samples from animal toxicity studies are used for the 'omics measurements:
1. Suitability of exposure conditions; 2. Magnitude of findings; 3. Persistence of findings; 4. Dose-response relationships; 5. Within-study consistency of findings; 6. Biological plausibility of 'omics-based findings; 7. Human (or environmental) relevance of findings.
Importantly, while the grades for each scoring criterion are defined based upon best practices (e.g., TGs, guidance documents, etc.), the assignment of specific scores requires expert judgement. For example, when assessing dose-response relationships (scoring criterion 4), a score of 3 is generally assigned to studies that include at least 3 appropriately spaced dose levels (plus control group), but for which the main findings to not exhibit a clear dose response. In practice, the interpretation of such a scenario has to be performed on a case-by-case basis, comparing the respective data recorded for the test groups with those of the vehicle control groups and with historical control data. The absence of a clear dose response can also be an indication that the findings are not treatmentrelated and therefore not potentially relevant (thereby yielding a score of 0).
Within any given study, there may be one, or more than one type of 'omics measurement (e.g. transcriptomics, proteomics, metabolomics). However, huge amounts of data may also be obtained when only one specific type of 'omics measurement is performed. Therefore, the evaluation of the consistency of findings is a critical factor in any 'omics-based study. This evaluation should not only address how well different findings match each other, but also how well they match the formulated hypothesis (cf. Table 2, descriptions of the different grades for the scoring criterion withinstudy consistency).
The assessment of the biological plausibility of 'omics-based findings is essential when evaluating 'omics data relevance. This assessment takes into consideration if the 'omics data can be related to a specific MoA, and if so, if this MoA reflects an adverse outcome that is relevant for the formulated hypothesis. Conceptual approaches such as adverse outcome pathways (AOPs; cf. Section 4 for definition) have been proposed to aggregate, evaluate and visualise the links between molecular and cellular perturbations with relevant adverse outcomes (Ankley et al., 2010) . As compared to MoAs, AOPs are substance-agnostic and not species-specific, and thus do not consider factors that are directly related to the exposure to a given substance, e.g., ADME. AOPs are the central element of a toxicological knowledge framework being built to support the Box 1 Calculation of the final study quality score.
The scoring sheet exemplified in Table 1 encompasses 8 specific scoring criteria, i.e. (1) test substance characterisation; (2) general experimental design; (3) mode of application of the test substance; (4) suitability of sampling method; (5) suitability of non-'omics parameters; (6) suitability of 'omics technologies; (7) accessibility of raw data (also taking into account the definition of 'omics raw data); (8) statistical analysis of findings. Operationally, evaluating suitability requires expertise in determining the appropriateness of the method for its intended purpose.
Using the respective graduations specified in Table 1 , each of the 8 scoring criteria is assigned a score between 0 and 4, and the scores are noted on the scoring sheet. Accordingly, the maximum score that a study could be awarded using the exemplary Table 1 is 8 Â 4 ¼ 32, if all scoring criteria are applicable.
Since the template for the scoring sheet has been specifically designed for a particular type of test method, all of its categories should generally be applicable to each of the studies whose quality is being assessed. However, a given LoE may include, e.g., the same type of 'omics-based study with or without concordant non-'omics measurements (e.g., adverse/clinical observations, clinical pathology, histopathology, etc.). To avoid creating bias if one of the 8 criteria is not applicable to a given study, the total score (i.e. maximum 32 in Table 1 ) is divided by the number of applicable scoring categories (i.e. maximum 8 in Table 1 ). Thereby, each study identified in the literature search is assigned a final study quality score of 0e4.
Importantly, a scoring category may only be excluded from this division if it is not applicable. If a score of 0 has been assigned because the study is of insufficient quality with respect to the given scoring criterion, this criterion has to be counted in the number of applicable scoring categories. assessment of a substance's hazard and risk based on mechanistic reasoning, e.g. under the OECD AOP programme (OECD, 2013) . Further, the assessment of the biological plausibility of 'omicsbased findings takes into consideration any available data on biological and temporal concordance and analogy (Section 1), evaluating if such data are either supportive, or not.
For those adverse effects where the AOP is well characterised, the assessment of the biological plausibility should be based primarily on the extent to which the available ('omics and non-'omics) data tend support to it, in particular, the extent to which essential key events of the AOP are confirmed (e.g. Becker et al., 2015) . At best, the adverse effect of concern in the test animal species should be known to be relevant for human or environmental health. However, for many adverse effects, the AOP is not known, poorly defined or too complex to be easily presented in linearized frameworks such as that of AOPs. In such cases, the biological plausibility of 'omics data will be less evident, and it may be appropriate to compare experimental findings ('omics data) with those of established reference substances to support WoE considerations. Of note, however, the establishment of reference substances for 'omics studies is a matter for further investigations.
Using the scoring sheet to assess data relevance that was developed for the given QWoE evaluation, the final 'omics data relevance score is assessed and calculated as described in Box 2.
Assessment of the relevance of non-'omics data (if applicable)
In many cases, animal studies do not only yield data from 'omics measurements, but also from non-'omics measurements. Depending on the test method, such non-'omics measurements can be, e.g., adverse or clinical observations, measurements of body weight and food/water consumption, pathology, gross pathology and organ weights, histopathology, etc.
Analogue to the assessment of 'omics data, the relevance of non-'omics measurements from the animal toxicity study is assessed using the scoring system described in Table 2 and Box 2. Notably, it may be necessary to record the relevance of distinct findings separately for different non-'omics measurements. In this case, the total score is divided by the number of distinct findings assessed thereby yielding the final relevance score for non-'omics data.
Weighting of the within-study relevance of 'omics data and non-'omics data (if applicable)
If the study whose relevance is being assessed contains both data from 'omics measurements and from non-'omics measurements, the relevance score for 'omics data and the (final) relevance score for non-'omics data have to be weighted. The following scenarios are conceivable:
i. The relevance score for 'omics data and the (final) relevance score for non-'omics data lie in the same order of magnitude (i.e. they are both either high (scores > 3.5e4), moderate (scores > 3.0e3.4), low (scores > 2.5e2.9), or insufficient (scores 2.5); score ranges set empirically based upon the scoring criteria grades described in Table 2 ; cf. Section 2.5.1 for further details on the setting of the threshold). o If the 'omics-based findings are further consistent with the non-'omics based findings, the overall study relevance score is calculated as mean of both values. o If the 'omics-based findings are not consistent with the non-'omics based findings, the further evaluation should proceed as described in scenario (ii) below. ii. The relevance score for 'omics data is lower than the relevance score for non-'omics data. o If the 'omics-based findings are further consistent with the non-'omics based findings, the non-'omics data are weighted two-fold higher than the 'omics data (overall final study relevance score ¼ [1 Â 'omics data relevance score þ 2 Â non-'omics data relevance score/3]). Deviations from this weighting are possible with justification (Box 3). o If the 'omics-based findings are not consistent with the non-'omics based findings, the relative weighting factor is determined on a case-by-case basis, taking into consideration the formulated hypothesis and providing justification for this weighting (Box 3). iii. The relevance score for 'omics data is higher than the relevance score for non-'omics data. In practice, this scenario is unlikely to occur. Applying the scoring criteria for data relevance Box 2 Calculation of the final 'omics data relevance score.
Based upon the specifications provided for 'omics data in Table 2 , each of the 7 criteria (listed above) is assigned a score between 0 and 4, and the respective scores are noted on the scoring sheet. Accordingly, the maximum score that a study could be awarded using the scoring sheet exemplified in Table 2 is 7 Â 4 ¼ 28, if all scoring criteria are applicable. Possibly, one or more scoring criteria are not applicable to critically test the given hypothesis. Therefore, the mean score is calculated by dividing the total score by the number of categories scored. Thereby, each study identified in the literature search is assigned a final 'omics data relevance score of 0e4.
A scoring category may only be excluded from the division if it is not applicable. If a score of 0 has been assigned because the study is of insufficient quality with respect to the given scoring criterion, this criterion has to be counted in the number of applicable scoring categories. If the hypothesis doesn't enable a ranking order for the weighting of findings, the default position is to dispense with weighting. On a case-by-case basis, a weighting may be based on the respective data relevance scores.
Because the weighting of the relevance of findings is liable to bias, the scientific rationale for any weighting must be described unambiguously.
Whenever the final study relevance score is calculated, the measure should be divided by the total number of weighting points (i.e. when applying a 1 þ 2 weighting, the divisor is 3, when applying a 1 þ 3 weighting, the divisor is 4, etc.). Thereby, it is ensured that the final study relevance score always ranges between 0 and 4.
(as exemplarily described in Table 3 ), highly relevant 'omics data are likely to be obtained from TG-compliant toxicity studies. Such studies should also yield highly relevant non-'omics data. If scenario (iii) does occur, it will require expert judgement to determine the relative weighting that shall be given to the 'omics and the non-'omics data. Again, a justification should be given to this weighting.
2.5.
Step 5: evaluation of the strength of evidence; individual lines of evidence Once all final study quality scores and final study relevance scores have been calculated for all studies that are included in the QWoE evaluation, the evaluation of the strength of the evidence (cf. Section 4 for definition) for each individual LoE begins. Whenever different studies are available for a single LoE, the final study quality scores and final study relevance scores assigned to each individual study contained in the LoE can be plotted graphically to aid the interpretation of the findings (Fig. 4) . Notably, one single LoE might also contain only one single study.
The line of evidence-specific average study quality scores and study relevance scores are calculated by the respective sums of all study-specific study quality/study relevance scores divided by the number of studies with study quality score !2.5. To not distort the overall average, the poor-quality studies J, K, and L (average study quality score <2.5) are excluded from this calculation (and a justification for this exclusion is provided).
Evaluation of study quality within lines of evidence
The first step of the evaluation of individual LoEs addresses the question if the studies contained within the LoE are of sufficient quality to conduct the QWoE evaluation. For this purpose, a threshold of 2.5 has been set to identify studies that are of insufficient quality for the QWoE evaluation. The threshold of 2.5 has been set empirically taking into account the scoring criteria and scores for study quality described in Table 1 , following the rationale that studies should only be considered to be of sufficient quality if they scored higher than 50% of the highest possible score (50% of 4.0 ¼ 2.0), but that it would be too restrictive to only consider studies that met the two highest scores (i.e. 4.0e3.0). By analogy, a threshold of 2.5 has been set for the data relevance score to distinguish sufficient from insufficient data relevance.
The following scenarios are conceivable in identifying the sufficiency of the quality of studies contained within a LoE:
None of the studies in the LoE have study quality scores 2.5. In this case, the LoE, as such, can be used for the further QWoE evaluation.
All studies in the LoE have study quality scores 2.5. In this case, it may be considered to exclude this LoE from the further evaluation. If, however, the respective LoE has been identified as essential for the QWoE evaluation (Step 1; Section 2.1.3), this appraisal may lead to the conclusion, that the uncertainties are too high to conclude on the QWoE evaluation (i.e. that the formulated hypothesis cannot be confirmed or refuted (Step 7; Section 2.7). Some studies in the LoE have study quality scores 2.5, whereas other studies have study quality scores >2.5. To prevent, e.g., several low-quality studies from overriding one high quality study, it may be decided to exclude the low-quality studies from the further evaluation.
In case LoEs or individual studies are excluded from the further evaluation, these LoEs and these studies should be clearly identified and a justification for their exclusion should be provided (e.g., as related to individual scoring criteria that received very low scores and an appraisal if the poorer scored studies all failed on the same scoring criterion, etc.).
On the theoretical scoring sheet presented in Fig. 4 , studies A-I have study quality scores >2.5 and are used for the further evaluation, whereas studies J, K, and L with study quality scores 2.5 are excluded from the further evaluation.
Strength of evidence, individual lines of evidence
To determine the strength of evidence of all individual LoEs, the final study quality and study relevance scores assigned to the individual studies that are conjoined in the respective LoEs are summated and divided by the total number of studies considered. This calculation yields the average study quality score and the average study relevance score for the individual LoE. These LoEspecific scores should always be presented jointly with the ranges of the study-specific study quality and study relevance scores (i.e. the respective minimum and maximum values).
The strength of evidence from a LoE is derived by multiplying the average study quality score by the corresponding average data relevance score. (Thereby, the LoE-specific strength of evidence can achieve a score ranging from 0 to 16.) The LoE-specific strength of evidence should always be represented with the ranges of the study-specific study quality and study relevance scores. Again, it is recommended to create a plot for better visualisation (Box 4).
Generally, all essential LoEs should have average study quality scores and average study relevance scores >2.5 in order to be able to support the hypothesis. Accordingly, their strength of evidence should generally attain scores >6.25 (2.5 Â 2.5 ¼ 6.25).
To ensure transparency of the QWoE evaluation, it is recommended to provide a tabular presentation for each LoE in addition Table 3 Integration of the lines of evidence to characterise uncertainties. 1. Study-specific study quality scores for each essential LoE
All study quality scores above 3.5
All study quality scores above 3
The majority of study quality scores above 2.5
Only some study quality scores above 2.5
None of the study quality scores above 2.5 2. Range of study-specific data relevance scores for each essential LoE Less than 0. Letters A-L refer to individual studies (AeI: 9 studies with study quality score !2.5). Fig. 5 . Hypothetical graph representing the study quality versus data relevance for all suitable lines of evidence. 1E, 2E, and 3S represent different lines of evidence (LoEs) that can encompass either only 'omics studies, or only non-'omics studies or a combination of both, depending on the hypothesis under investigation. The numbers refer to the relative weighting assigned to the given LoE. The letter E indicates that the LoE is essential to critically test the hypothesis and the letter S that it is supportive. While the LoEs are plotted using the LoE-specific average study quality and study relevance scores, the arrows indicate the respective ranges of the study-specific study quality and study relevance scores that are conjoined in the respective LoEs.
to the graphical presentation. This table should include the following columns:
The nature of the LoE; The rank order for that LoE and the indication if it is essential or supportive;
The average study quality score (value 0e4) and the range of study-specific study quality scores;
The specification if studies with quality scores 2.5 have been excluded from a LoE that contains both high quality studies and lower quality studies, including the justification for doing so (Step 5; Section 2.5.1); The average study relevance score (value 0e4) and the range of study-specific study relevance scores; The strength of evidence for the LoE (value 0e16).
2.6.
Step 6. integration of lines of evidence: scoring for the overall strength of evidence to support or decline the hypothesis
Once the average study quality scores and average study relevance scores as well as the strength of evidence have been calculated for all potentially suitable LoEs, the overall strength of evidence to support or decline the hypothesis is assessed. Depending on the nature of the hypothesis, one or more LoEs may need to be considered (Fig. 2) . Therefore, this step of the QWoE evaluation involves integrating the strength of evidence from the individual LoEs to determine whether, or not, the overall strength of evidence from the QWoE evaluation is sufficient to derive a conclusion on the hypothesis.
To integrate the evidence from all available suitable LoEs, it has to be assessed if:
i. The specific findings from the LoEs are supportive of the hypothesis, or not; AND ii. The strength of evidence is sufficient to confirm or decline the hypothesis, as applicable.
If the specific findings from the LoEs are consistently supportive (or consistently not supportive) of the hypothesis, the QWoE evaluation proceeds directly to the characterisation of uncertainties and the conclusion on the QWoE evaluation (Step 7; Section 2.7).
Whenever different LoEs show discrepancies in findings, these discrepancies need to be identified and assessed. This assessment should take into account the weighting of LoEs (Step 1; Section 2.1.3) and the average study quality and study relevance scores of the respective LoEs (that determine the LoE-specific strength of evidence). In order to support the hypothesis, the findings from high ranking essential LoEs should generally fit the hypothesis. Further, these high ranking essential LoEs should provide strong evidence to indicate strong support for the hypothesis.
To produce a final score for the overall strength of evidence of the QWoE, the LoE-specific strengths of evidence (Step 5; Section 2.5.2) are added and divided by the number of LoEs. Just as the LoEspecific strength of evidence, the overall strength of evidence of the QWoE can achieve a score ranging from 0 to 16. The interpretation of the overall strength of evidence scores is based on the following empirical score banding to support the hypothesis:
Very strong support >12.0e16.0 (with all scores > 9.0) Strong support > 8.0e12.0 (with all scores > 6.25) Reasonable support > 5.0e8.0 (with all scores > 4.0) Insufficient support 5.0 This scoring system is based upon the threshold of >6.25 that was set to identify LoEs with sufficient strength of evidence to support the hypothesis (cf. Section 2.5.2), and that in turn is based upon the threshold of >2.5 that was set to identify sufficient study quality and data relevance (cf. Section 2.5.1): To be able to conclude on 'strong support' for the hypothesis, all individual essential LoEs should score >6.25. To be able to conclude on 'reasonable support', the overall QWoE score should range around >6.25 (i.e. > 5.0e8.0). An overall QWoE score of 5.0 should not be considered as providing sufficient support for the hypothesis that substance A causes effect B. Indeed, if the support for the hypothesis is 5.0 and the characterisation of uncertainties allows concluding that the uncertainties are 'acceptable' (Step 7; Section 2.7.1), then the conclusion should be that substance A does not cause effect B.
2.7.
Step 7: characterisation of uncertainties; conclusion on the QWoE evaluation 2.7.1. Characterisation of uncertainties
The outcome of the integration of the LoEs, i.e. the scoring for the overall strength of evidence to support the hypothesis, is used to characterise the uncertainties involved in the QWoE evaluation. Some uncertainty is inevitable in any hazard assessment (or other (eco)toxicological or biological study). Therefore, the characterisation of uncertainties addresses the question whether the uncertainties are 'acceptable' or not. Table 3 presents the criteria that should be addressed when assessing uncertainties further providing a grading score of 0e4 for each criterion. Using these criteria, the level of uncertainty involved in the QWoE evaluation should be determined on a case-by-case basis and a justification for the decision should be provided. A low score (0e1) in any of the criteria can imply that the uncertainty is not acceptable. For instance, if there are a number of serious data gaps (criterion 4; scoring grade 1), the quality, relevance or consistency of the (few) available data (criteria 1e3) are subordinate.
Conclusion on the QWoE evaluation
The final step of the QWoE evaluation is to consider the confidence in the conclusion of the support for the hypothesis (e.g. that substance X causes effect Y under conditions Z). This final evaluation should take into account the score for the overall strength of evidence described in Step 6 (Section 2.6). Importantly, however, the final conclusion on the QWoE evaluation requires expert judgement, and it should always be conducted on a case-by-case basis. While the QWoE framework has been developed to foster transparency and consistency of WoE evaluations, it does not render expert judgement expendable. Since the scores and thresholds do not represent 'bright lines' defined in legal texts or
Box 4
Graphical representation of LoE-specific average study quality and study relevance scores Fig. 5 exemplarily presents a graph on which different LoEs are represented by their average study quality scores and average study relevance scores, while also indicating the respective ranges of individual study quality and study relevance scores.
A colour code or other distinguishing form can be used in the graphical presentation to indicate the ranking (weighting) of the LoEs (Step 1; Section 2.1.3). In Fig. 5 , the LoEs are named 1E, 2E, 3S, with the number indicating the rank order and the letters E or S the essentiality or supportiveness of the LoEs.
science-based standards, deviations from the scheme (e.g., conclusions of the WoE based upon LoEs with lower average scores) are permissible with justification.
As a general rule, however, if the overall strength of evidence is based on high average study quality scores and high average study relevance scores, the evidence is likely to be sufficient to derive a conclusion, just as it is likely to be insufficient if both of these scores are low. If the average study quality scores are low, but the average study relevance scores are high, the evidence is potentially supportive of the hypothesis. If the average study quality scores are high, but the average study relevance scores are low, the evidence is potentially non-supportive of the hypothesis.
The threshold of 2.5 to distinguish low from high scores is also applied for these considerations: The overall strength of evidence to derive a decisive conclusion from the QWoE evaluation to either support or decline the formulated hypothesis generally requires that the average study quality scores for all essential LoEs is > 2.5. If the QWoE conclusion is based upon essential LoEs with study quality scores below this threshold, this should be clearly justified taking into account the implications of basing regulatory decisions on poor-quality data. Further, generally, all essential LoEs should have high average study relevance scores (>2.5) in order to be able to support the hypothesis. It should be noted that low LoE-specific average data relevance scores can arise for two very different reasons:
i. The studies are not suitable to critically test the hypothesis. ii. The studies are suitable to critically test the hypothesis, but the findings do not support the hypothesis.
Depending on the specific findings recorded for a given LoE, the scenario is also conceivable that the LoE has a high average data relevance score, but that the specific findings recorded in the individual studies do not support the hypothesis.
Options if QWoE analysis is inconclusive
From a hazard assessment perspective, if the level of uncertainty is deemed too high to conclude on the WoE, there are four options.
1. To reconsider the suitability of the hypothesis for the intended purpose; 2. To conduct a further search for additional suitable studies that can be scored for quality and relevance (to avoid bias, the choice of the new search terms should be justified); 3. To prioritise the performance of specific studies to fill the important data gaps; 4. To identify an appropriate closely related data-rich substance or group of substances to allow extrapolation of the corresponding data to the substance of interest, e.g., using read-across as described in the Read-Across Assessment Framework (ECHA, 2015) .
Conclusion
In this article, a framework for the QWoE analysis of 'omics data for regulatory purposes has been presented that includes the scenarios that 'omics data are either evaluated on their own or in combination with non-'omics data. This QWoE framework is based upon a general QWoE framework without specific consideration of 'omics studies that was trialled successfully for human and environmental hazard assessment (Bridges and Solomon, 2016; Dekant and Bridges, 2016a, b) . Case studies addressing the QWoE evaluation of 'omics data (alone or in combination with non-'omics data) are recommended to put the QWoE framework presented herein into practice. In such case studies, that could be conducted within the ECETOC Transformational Programme "Using molecular data wisely" (http://www.ecetoc.org/scienceprogramme/transformational-programmes/), the relevance of the different steps of the QWoE framework (including the empirically set cut-off values) can either be confirmed, or further refined. It is recognised that the practicability of the grading scores as exemplarily suggested in the tables of this article remains to be established. In any case, the templates for the scoring sheets and the grading scores they contain should always be adapted to the scope of any given QWoE (i.e. the formulated hypothesis). As the QWoE framework represents a generic approach to evaluate LoEs for a given hypothesis, the proposed approach can easily be adopted to fit LoEs spanning multiple levels of organisation and thus support AOP development and evaluation.
The establishment of a formal framework enabling quantitative conclusions of WoE evaluations that include 'omics data constitutes an important step to facilitate the utilisation of 'omics data for regulatory purposes. A quantitative methodology is less vulnerable to bias, since bias can be introduced at many points in the assessment including data selection, evaluation, interpretation and the weighing of evidence itself. The regulatory use of 'omics data requires that study outcomes are transparent, consistent and reproducible. The QWoE framework presented herein has been developed to harmonise this use, also across different industrial sectors and between different jurisdictions.
Definitions
The following list provides definitions of key terms used in the present article.
Adaptive (non-adverse) effect: A biological effect that does not cause biochemical, behavioural, morphological or physiological changes that affect the general well-being, growth development or life span of an animal (ECETOC, 2002) .
Adverse effect: Change in the morphology/physiology (and pharmacology), growth, development, reproduction, or, life span of an intact organism, or a system or (sub)population, that results in an impairment of functional capacity, an impairment of the capacity to compensate for additional stress, or an increase in susceptibility to other influences (WHO/IPCS, 2009).
Adverse outcome pathway (AOP): A linear sequence of key events from a molecular initiating event to an adverse effect at the individual level (for human health) or population level (for environmental health) (Ankley et al., 2010) . Unlike modes-of-action (cf. definition), AOPs are substance-agnostic and not species-specific, and thus do not consider factors that are directly related to the exposure to a given substance, e.g., ADME (ECETOC, 2017) .
Consistency (within study): All parameters recorded in an in vivo or in vitro study allow concluding on the same adverse effect(s) or MoA (ECETOC, 2017) .
Consistency (amongst different studies): The same adverse effect, or MoA, as applicable, is recorded in different in vivo or in vitro studies, as applicable (ECETOC, 2017) . When integrating the lines of evidence (cf. definition), all outcomes match the hypothesised MoA.
Hypothesis: The question or problem formulated at the onset of any study. Generally, the hypothesis takes the form of does substance of interest 'X' cause adverse effect 'Y'/have MoA 'Y' under conditions 'Z'. (Conditions include, e.g., exposure levels and duration, and species of interest.)
Lines of evidence (LoE): Depending on the formulated hypothesis, a LoE conjoins different (types of) studies that are used to critically test the hypothesis, e.g. experimental studies using human volunteers or epidemiological observations, animal studies, in vitro studies, or in silico modelling. As appropriate, LoEs may include different study types or only one specific study type (e.g., all animal studies that are relevant to test the hypothesis, or only those studies conducted in accordance to a given OECD TG).
Mode-of-action (MoA): The biologically plausible sequence of substance-specific key events, starting with exposure and proceeding through the interaction of the substance or its metabolites with a cell, through functional and anatomical changes leading to an observed effect supported by robust experimental observations and mechanistic data (Sonich-Mullin et al., 2001; Boobis et al., 2009; Fenner-Crisp and Dellarco, 2016) .
Overall weight of evidence: A summation of the findings from all suitable LoEs (containing all suitable studies). The overall WoE may be presented graphically as a plot of LoE-specific average study quality scores against LoE-specific average study relevance scores further indicating the ranges of study-specific study quality and study relevance scores.
Quality (reliability): The inherent quality of a study relating to preferably standardised methodology and the way that the experimental procedure and results are described to give evidence of the clarity and plausibility of the findings (Klimisch et al., 1997; Kase et al., 2016; Moermond et al., 2016) . Study quality provides a measure of the reliance that can be placed on its findings for the purpose of critically testing the hypothesis.
Quantitative weight of evidence (QWoE): The testing of a hypothesis (cf. definition) by the critical weighting of all available, potentially relevant studies using pre-defined, scientifically justified criteria to score for both the quality (reliability) of studies and the relevance of findings to characterise quantitatively the strength of evidence.
Relevance: The extent to which a study and its results can be generalised and applied to either humans or ecological species for a given purpose (i.e. to critically test the hypothesis) (ECETOC, 2017) .
Strength of evidence: For a particular study, this is derived by multiplying the study quality score by the corresponding data relevance score. For a particular LoE, this is derived by multiplying the average study quality score by the corresponding average data relevance score.
Weight of evidence (WoE): The identification and objective analysis (using pre-defined, scientifically justified criteria) of all potentially relevant studies, for their quality and relevance in critically testing a hypothesis.
Weighting of lines of evidence: The relative ranking of LoEs to reflect the relative importance of different types of data and/or different LoEs (cf. definition) in critically testing the formulated hypothesis.
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